Stay updated on Pembrolizumab for HR+ Inflammatory Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for HR+ Inflammatory Breast Cancer Clinical Trial page.

Latest updates to the Pembrolizumab for HR+ Inflammatory Breast Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedAdded a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.SummaryDifference3%
- Check23 days agoChange DetectedUpdated the page version from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.1%
- Check37 days agoChange DetectedAdded: Last Update Posted (Estimated) and Revision: v3.0.2; Deleted: Last Update Posted, Revision: v3.0.1, and Back to Top. This indicates the page now reports an estimated update time and uses a newer version, with a minor removal of a navigation element.SummaryDifference0.2%
- Check44 days agoChange DetectedThe webpage has updated its version from v3.0.0 to v3.0.1 and has removed outdated dates from March and April 2025, replacing them with new dates in September 2025.SummaryDifference0.7%
- Check52 days agoChange DetectedThe web page has added a facility name and location related to skin and connective tissue diseases, along with the mention of pembrolizumab, while removing various location details and specific disease-related resources.SummaryDifference2%
- Check66 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab for HR+ Inflammatory Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for HR+ Inflammatory Breast Cancer Clinical Trial page.